Clinical Trials Browser

Urinary Bladder Neoplasms, Carcinoma, Hepatocellular, Mesothelioma, Ovarian Neoplasms, Paraganglioma, Pheochromocytoma, Sarcoma, Stomach Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma

NCT06083844 2026-05-18

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

Phase 2 Recruiting

20 enrolled

Gynecologic

Ovarian Neoplasms

NCT07285044 2026-05-18

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

Phase 2 Recruiting

27 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidMyeloidPlasma cellThoracic

Amyloidosis, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Hodgkin Disease, Lung Neoplasms, Melanoma, Multiple Myeloma, Myelodysplastic Syndromes, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Lymphoma, Mantle-Cell

NCT06172478 2026-05-15

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 2 Recruiting

740 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT07586826 2026-05-14

N01-A-PICIT-GT

Phase 2 Recruiting

220 enrolled

BreastClassical hematologyGynecologicThoracic

Pathologic Complete Response, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Thrombocytopenia, Endometrial Neoplasms

NCT04550494 2026-05-13

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Phase 2 Recruiting

36 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT04918186 2026-05-12

IPROC

Phase 2 Recruiting

60 enrolled

Gynecologic

Ovarian Neoplasms

NCT06760819 2026-05-07

panSOHO

Phase 2 Recruiting

111 enrolled

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors

NCT06023862 2026-05-06

DOVE

Phase 2 Recruiting

198 enrolled

Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT05128825 2026-05-01

DENALI

Phase 2 Recruiting

310 enrolled

Gynecologic

Ovarian Neoplasms

NCT06180356 2026-04-22

ANALLISA

Phase 2 Recruiting

30 enrolled

Gynecologic

Ovarian Neoplasms

NCT06769152 2026-04-22

A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors

Phase 2 Recruiting

190 enrolled

Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms

NCT07303387 2026-04-21

EZHiSWITCH

Phase 2 Recruiting

900 enrolled

Gynecologic

Ovarian Neoplasms

NCT07340164 2026-04-20

TROY

Phase 2 Recruiting

116 enrolled

Gynecologic

Ovarian Neoplasms, Recurrence

NCT05123807 2026-04-16

Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)

Phase 2 Recruiting

30 enrolled

Gynecologic

Ovarian Neoplasms

NCT07303894 2026-04-16

A Study of Isoquercetin in People With Ovarian Cancer

Phase 2 Recruiting

90 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT06906341 2026-04-14

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Phase 2 Recruiting

270 enrolled

Gynecologic

Fallopian Tube Diseases, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Diseases, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms

NCT05183984 2026-04-13

NIRVANA-1

Phase 2 Recruiting

390 enrolled

Gynecologic

Ovarian Neoplasms

NCT05887609 2026-04-13

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

Phase 2 Recruiting

53 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06695845 2026-04-09

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Phase 2 Recruiting

200 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06290193 2026-04-01

Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery

Phase 2 Recruiting

86 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06365853 2026-03-25

A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

Phase 2 Recruiting

100 enrolled

Gynecologic

Ovarian Neoplasms

NCT04919629 2026-03-23

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Phase 2 Recruiting

60 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05489211 2026-03-19

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Phase 2 Recruiting

454 enrolled

GastrointestinalGynecologic

Biliary Tract Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05231122 2026-03-16

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Phase 2 Recruiting

80 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07050771 2026-03-12

Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery

Phase 2 Recruiting

148 enrolled

GenitourinaryGynecologic

Urinary Bladder Neoplasms, Kidney Neoplasms, Neoplasms, Ovarian Neoplasms

NCT05952453 2026-03-11

Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro

Phase 2 Recruiting

20 enrolled

Gynecologic

Ovarian Neoplasms

NCT06268665 2026-03-04

Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy

Phase 2 Recruiting

86 enrolled

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT07447050 2026-03-03

Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial

Phase 2 Recruiting

24 enrolled

BreastGastrointestinalGynecologicHead & NeckSarcomaThoracic

Breast Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms, Urogenital Neoplasms, Colorectal Neoplasms

NCT07033819 2026-02-27

Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib

Phase 2 Recruiting

48 enrolled

Gynecologic

Ovarian Neoplasms

NCT06494150 2026-02-23

Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)

Phase 2 Recruiting

37 enrolled

Gynecologic

Ovarian Neoplasms

NCT05460000 2026-02-12

N-Plus

Phase 2 Recruiting

640 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

NCT06330064 2026-02-12

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

Phase 2 Recruiting

520 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Recurrence, Colorectal Neoplasms, Endometrial Neoplasms

NCT05465941 2026-02-09